Arbeitsgruppenleiter

Leyen v. d., Heiko

Leyen v. d., Heiko , Prof. Dr. med.

Arbeitsgruppenleiter

REBIRTH Unit Clinical Trial Management

Hannover Clinical Trial Center GmbH
Carl-Neuberg-Str. 1/K27 - OE 9751
30625 Hannover

vdleyen(at)clinical-trial-center.de

Biography / About

Date of Birth:June, 1955
Function:Managing Director

Education:

1975 - 1976Chemistry, University of Hannover
1979 - 1986M.D., Hannover Medical School (MHH)

Academic appointments and Research posts:

1986 - 1988Post doc, Institut of Pharmacology, University of Hamburg
1988 - 1992 and 1996 - 1998Internal Medicine and Cardiology, MHH
1992 - 1995Research Fellow, Falk Cardiovascular Research Center, Division of Cardiovascular Medicine, Stanford, CA, USA
1995 - 1996Instructor in Medicine and Junior Faculty member, Stanford University, Division of Cardiovascular Medicine; Supervisor, CV Gene Transfer Group

Other professional activities:

1998 - 2001Medical Director and Vice President Clinical Development, Cardion AG, Erkrath
2001 - 2002Chief Scientific Officer, ARTISS GmbH, Hannover
2003 - 2004Chief Scientific Officer, AVONTEC GmbH, München
Since 2005Managing Director, Hannover Clinical Trial Center

Awards and Prizes:

1986Research Award, German Research Foundation
1992Habilitation Research Award, German Research Foundation
1994Trainee Investigator-Award, American Federation for Clinical Research
1995Excellence in Research-Award, Stanford University
1995Annual Award, German Heart Foundation

Major research interests:

  • Translational medicine
  • Regulatory framework of clinical research
  • Precision medicine
  • Gene therapy
  • European collaborative clinical research

Selected Publications:

  1. Voelkel C, Lührmann A, Baum C, von der Leyen HE. Retrovirus mediated hematopoietic gene therapy: A European regulatory perspective with special focus on the situation in Germany. Cell Ther Transplant. 2009;1:e.000044.01. doi:10.3205/ctt-2009-en-000044.01
  2. Lührmann A, Tschernig T, von der Leyen H, Hecker M, Pabst R, Wagner AH. Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model. Exp Lung Res. 2010;36:85-93.
  3. von der Leyen HE, Mügge A, Hanefeld C, Rupprecht HJ, Hamm CW, Zeiher, A, Fichtlscherer S. REGENT1 – A prospective single-blind multicenter dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion. Hum Gene Ther. 2011; 22:951-8; first online Nov 19, 2010
  4. Walter C, Rohde B, Wicke DC, Pohler C, Lührmann A, von der Leyen H. Klinische Entwicklung neuartiger Therapien: Vom Labor zur klinischen Prüfung. Bundesgesundheitsblatt. 2011;54: 803-810
  5. Pincha M, Sundarasetty BS, Salguero G, Gutzmer R, Garritsen H, Macke L, Schneider A, Lenz D, Figueiredo C, Blasczyk R, Ruggiero E, Schmidt M, von Kalle C, Puff Ch, Modlich U, von der Leyen H, Wicke DC, Ganser A, Stripecke R (2012). Identity, Potency, In Vivo Viability, and Scaling Up Production of Lentiviral Vector-Induced Dendritic Cells for Melanoma Immunotherapy. Hum Gene Ther 23:38-55
  6. Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles Ch, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggenenti PL, Rychlik I, Spasovski G, Rossing P (2016) Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): Essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 6:e010310 doi:10.1136/bmjopen-2015-010310
  7. Samuels S, Balint B, von der Leyen H, Hupé P, de Koning L, Kamoun C, Luscap-Rondof W, Wittkop U, Bagrintseva K, Popovic M, Kereszt A, Berns E, Kenter GG, Jordanova ES, Kamal M, Scholl S (2016) Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study. Br J Cancer. 115(12):1575-1583. doi: 10.1038/bjc.2016.340.
  8. Scheper V, Leifholz M, von der Leyen H, Keller M, Denkena U, Koch A, Karch A, Miller J, Lenarz Th (2016) ACEMg-mediated hearing preservation in cochlear implant patients receiving different electrode lengths (PROHEARING): study protocol for a randomized controlled trial. Trials. 2016; 17: 394. Published online 2016 Aug 8. doi: 10.1186/s13063-016-1526-7
  9. Deterding K, Spinner C, Schott E, Welzel W,Gerken G, Klinker H, Spengler U, Wiegand J, Schulze zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner Z, Zeuzem St, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H, the HepNet Acute HCV IV Study Group (2016) Six weeks of ledipasvir/sofosbuvir treatment of acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study. Lancet Inf Dis, published online October 28, 2016; dx.doi.org/10.1016/S1473-3099(16)30408-x
  10. Grählert X, Coch Ch, von der Leyen H, Bruns I (2017) Auswirkungen der Verordnung (EU) Nr. 536/2014 auf die akademische klinische Forschung aus der Sicht des Netzwerke der Koordinierungszentren für klinische Studien (KKS-Netzwerk) . Medizin und Ethik. Schriftenreihe des Arbeitskreises der Ethik-Kommissionen in Deutschland , Bd. 28, 43-56


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden